Starting May 1, new medications for contraception, IVF, and endometriosis will be included in the Pharmaceutical Benefits Scheme (PBS), allowing women to save thousands annually. This federal government decision, announced on Sunday, has been praised by health advocates who argue that women's health issues have been overlooked for too long.
Health Minister Mark Butler emphasized that the initiative aims to enhance Medicare, reduce medication costs, and address women's health concerns, rather than merely attracting female voters. He noted that women have long expressed frustration over the lack of attention to their reproductive health needs, including contraception and menopause.
David Littleproud, leader of the Nationals, expressed support for the initiative, highlighting it as part of a $580 million package for women's health. Deputy Liberal leader Sussan Ley also welcomed the news.
Among the newly subsidized drugs is drospirenone, a progesterone-only contraceptive pill branded as Slinda. This is the first contraceptive pill added to the PBS in 30 years, potentially benefiting over 100,000 Australian women by saving them more than $250 annually.
Dr. Nisha Khot, vice-president of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, expressed her satisfaction with the inclusion, noting that the new pill is particularly beneficial for women who cannot use oestrogen-based contraception.
Additionally, a new endometriosis treatment, relugolix with estradiol and norethisterone (marketed as Ryeqo), will be available on the PBS. This treatment is designed for those experiencing moderate to severe pain unrelieved by other medications. The government estimates that 8,500 women will benefit from this listing each year, saving them over $2,700 annually.
Sylvia Freedman from EndoActive praised the government's commitment but urged further investment in endometriosis treatment, research, and education. She highlighted the financial burden women face due to essential period-related costs.
Furthermore, women undergoing IVF will gain earlier access to Pergoveris (follitropin alfa with lutropin alfa) through the PBS, starting April 1. This treatment, previously available only in later IVF cycles, will now be accessible earlier for women with specific hormone deficiencies. The maximum number of Pergoveris pens per prescription will double, benefiting over 6,000 women annually.
Dr. Khot called for a comprehensive review of PBS and Medicare Benefits Scheme rebates with a focus on gender equity, emphasizing the need to address longstanding disparities.